| pubmed-article:18648657 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C0175677 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C0085508 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C0026724 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C1704242 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C0015620 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C1579762 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:18648657 | lifeskim:mentions | umls-concept:C0069562 | lld:lifeskim |
| pubmed-article:18648657 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18648657 | pubmed:dateCreated | 2008-7-23 | lld:pubmed |
| pubmed-article:18648657 | pubmed:abstractText | The clinical efficacy of gastroprotective drugs or low-dose H(2) receptor antagonists in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine in Helicobacter pylori (H. pylori)-negative healthy volunteers taking NSAID. This study was a randomized, two way crossover study comparing the preventive effect rebamipide 100 mg, t.i.d. and famotidine 10 mg, b.i.d against indomethacin (25 mg, t.i.d.)-induced gastric mucosal injury in H. pylori-negative healthy volunteers. 12 subjects satisfied criteria and were randomized. Endoscopy was performed at baseline and again after the treatment for 7 days, and symptoms were recorded during the treatment. Tissue levels of lipid peroxides and myeloperoxidase and serum indomethacin concentrations were also measured. Subjective symptoms were developed in 58% (7/12) of the rebamipide group, and in 75% (9/12) of the famotidine group (no significant differences). The incidence of gastric lesions (modified Lanza score 2 or higher) was 17% (2/12) in the rebamipide group and 25% (3/12) in the famotidine group. Peptic ulcers did not occur in both groups. There were no significant differences in tissue levels of lipid peroxide and myeloperoxidase and serum level of indomethacin between two groups after the treatment. In conclusion, these data recommend rebamipide (100 mg, t.i.d.) or famotidine (10 mg, b.i.d.) for the prevention of acute gastric injury induced by NSAID in patients without a particular risk factor. | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18648657 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18648657 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:18648657 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18648657 | pubmed:issn | 0912-0009 | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:YoshikawaTosh... | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:NaitoYujiY | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:TakagiTomohis... | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:HandaOsamuO | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:YagiNobuakiN | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:KokuraSatoshi... | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:BokuYoshioY | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:ImamotoEikoE | lld:pubmed |
| pubmed-article:18648657 | pubmed:author | pubmed-author:IinumaShojiS | lld:pubmed |
| pubmed-article:18648657 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18648657 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:18648657 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18648657 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18648657 | pubmed:pagination | 34-40 | lld:pubmed |
| pubmed-article:18648657 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18648657 | pubmed:articleTitle | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine. | lld:pubmed |
| pubmed-article:18648657 | pubmed:affiliation | Medical Proteomics, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. | lld:pubmed |
| pubmed-article:18648657 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18648657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18648657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18648657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18648657 | lld:pubmed |
